DEA Cannabis Rescheduling Hearings End, Industry Eyes Federal Shift
Federal rescheduling hearings wrap up as cannabis sector anticipates regulatory breakthrough that could reshape taxation and banking access.
The DEA's administrative hearings on cannabis rescheduling have concluded, marking a critical juncture in the federal government's potential shift from Schedule I to Schedule III classification. Industry stakeholders view the completion of this procedural phase as progress toward resolving decades of federal prohibition that has constrained legitimate cannabis businesses through punitive tax structures and limited banking access.
A Schedule III reclassification would eliminate the 280E tax provision that prevents cannabis companies from deducting standard business expenses, potentially boosting profit margins by 15-40% across the sector. Multi-state operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF) stand to benefit most significantly given their scale and current tax burdens that often exceed $100 million annually per company.
The hearings addressed technical aspects of cannabis's medical utility and abuse potential - key criteria for scheduling decisions under the Controlled Substances Act. While the DEA maintains final authority over rescheduling, the Biden administration's support for the move and the Department of Health and Human Services' recommendation create favorable political momentum. The process now enters a deliberative phase where the DEA reviews testimony and evidence before issuing a final rule.
Beyond immediate tax relief, rescheduling could accelerate institutional investment in cannabis equities and enable interstate commerce frameworks that currently operate in legal gray areas. The sector has struggled with limited access to traditional banking services and capital markets, constraining growth despite state-level legalization covering 70% of the US population. Federal rescheduling would not fully legalize cannabis but would represent the most significant federal policy shift since prohibition began.
The timeline for a final DEA decision remains uncertain, though industry observers expect resolution within the next 6-12 months. Cannabis stocks have already priced in some rescheduling optimism, with the AdvisorShares Pure US Cannabis ETF (MSOS) gaining 25% since the initial HHS recommendation surfaced. However, the sector continues trading at substantial discounts to traditional consumer goods companies despite comparable revenue growth rates, suggesting significant upside potential if federal barriers diminish.